Get started
Author

David D. Halbert

Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2020 · Jim P. Abraham, Daniel Magee, et al. · Clinical Cancer Research · 65
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach
2017 · Valeriy Domenyuk, Zhenyu Zhong, et al. · Scientific Reports · 51
PDF
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
2018 · Valeriy Domenyuk, Zoran Gatalica, et al. · Nature Communications · 26
PDF
Translocation of a Cell Surface Spliceosomal Complex Induces Alternative Splicing Events and Lymphoma Cell Necrosis
2019 · Sonal S. Tonapi, Vaishali Pannu, et al. · Cell chemical biology · 10
PDF
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
2025 · J. Abraham, V. Domenyuk, et al. · Scientific Reports · 9
PDF
Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets
2018 · V. Domenyuk, X. Liu, et al. · Annals of Oncology · 6
Validation of a whole exome/whole transcriptome liquid biopsy assay with correction for clonal hematopoiesis.
2023 · Nieves Perdigones Borderias, Jim Abraham, et al. · Journal of Clinical Oncology · 4
PDF
Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.
2018 · Valeriy Domenyuk, Daniel Magee, et al. · Journal of Clinical Oncology · 2
AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncology
2025 · Jim Abraham, Valeriy Domenyuk, et al. · medRxiv
PDF
Abstract 2300: AI enabled whole exome& transcriptome liquid biopsy addressing MCED, MRD, and therapy selection on a single platform
2024 · Jim Abraham, Valeriy Domenyuk, et al. · Cancer Research
Figure S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
PDF
Table S5 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S4 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Figure S1 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
PDF
Table S1 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Figure S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
PDF
Table S4 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Figure S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Figure S1 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Figure S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S5 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Table S1 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
2023 · Jim P. Abraham, Daniel Magee, et al.
Works count: 32
Citation count: 173
H-index: 6
I10-index: 4
Year
Topic
Type